Quantification of Signal Transduction Pathway Activity in Pancreatic Ductal Adenocarcinoma.
Saved in:
| Title: | Quantification of Signal Transduction Pathway Activity in Pancreatic Ductal Adenocarcinoma. |
|---|---|
| Authors: | Raymakers L; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.; Division of Imaging & Oncology, University Medical Center Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Daamen LA; Division of Imaging & Oncology, University Medical Center Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.; Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Intven MPW; Department of Radiotherapy, Division Imaging and Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Leusen JHW; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Olofsen PA; Center for Translational Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., van de Stolpe A; Drug Companion Diagnostics Company (DCDC-Tx), Eikenheuveldreef 16, 5263 EM Vught, The Netherlands., Raymakers RAP; Drug Companion Diagnostics Company (DCDC-Tx), Eikenheuveldreef 16, 5263 EM Vught, The Netherlands. |
| Source: | International journal of molecular sciences [Int J Mol Sci] 2025 Nov 25; Vol. 26 (23). Date of Electronic Publication: 2025 Nov 25. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
